Global healthcare communications agency Fishawack Health acquired Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the United States.
Over the last few years, there has appeared to be big interest on the part of biopharma in leveraging artificial intelligence (AI) and machine learning to improve trial design and speed up drug development. Another related category is digital therapeutics (DTx), which the Digital Therapeutics Alliance says, “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage or treat a broad spectrum of physical, mental and behavioral conditions.”
Imagine a financial ecosystem that interconnects payers and providers. It’s essential to the financial well-being of any provider organization, but the current claims and payment system is inefficient and outdated. Transparency, technology and trust are 3 critical elements to evolve the payer-provider relationship for fewer denials, patient payment estimations, reduced administrative costs and more.
Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.
Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.
Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.
Consolidation has dominated healthcare news over the past few years. Mergers between hospitals, payers, clinics, and other healthcare organizations are turning an ecosystem of individual stakeholders into one dominated by a few giants.
Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area are not living up to expectations.
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.